SUBSCRIBE
SUBSCRIBE

Biogen

NEWS
Small Cambridge Biotech Warp Bio Scores $387M R&D
Business
Biogen Throws Another $200M at Aducanumab With Amended Deal With Neurimmune
Despite the failures of late stage ALZ’s drugs developed by numerous companies, Biogen seems confident in the future of its amyloid plaque targeting aducanumab.
October 24, 2017
 · 
2 min read
 · 
Alex Keown
Genetown
Biogen And Celgene: Which Is The Better Buy Right Now?
October 10, 2017
 · 
1 min read
Drug Development
Biogen’s Alzheimer’s Pipeline Gets Some More Love
October 6, 2017
 · 
1 min read
Drug Development
A Frustrating Quest: Why Biogen Could Be Our Best Hope For Alzheimer’s Right Now
September 28, 2017
 · 
1 min read
Tiny KalVista Explodes on $760 Million Deal With Drug Giant Merck & Co.
Business
Tiny Bicycle Therapeutics Wrangles a $424 Million R&D Pact With Biogen Spinoff Bioverativ
September 6, 2017
 · 
2 min read
Longtime Biogen Exec Jumps Ship to Become COO of Scangos' Bay Area Startup
Business
Longtime Biogen Exec Jumps Ship to Become COO of Scangos’ Bay Area Startup
August 29, 2017
 · 
3 min read
Investors Sigh With Relief as Biogen's Alzheimer's Drug Delivers in Early-Stage Study
Drug Development
Biogen Shows Off More Positive Alzheimer’s Trial Data
August 28, 2017
 · 
3 min read
Investors Sigh With Relief as Biogen's Alzheimer's Drug Delivers in Early-Stage Study
Drug Development
Biogen Gained $1 Billion Overnight After Becoming Goldman Sachs’ Favorite Biotech
August 17, 2017
 · 
3 min read
Harmony Biosciences Gains U.S. Rights to Pitolisant, Raises $270 Million
Business
Vicarius Pharma Launches With $21.8 Million and Will be Helmed by Former Biogen-Elan Exec
August 14, 2017
 · 
2 min read
Load More
AWARDS
  • 2022 Best Places to Work
  • 2023 Best Places to Work
JOBS
IN THE PRESS
Genetown
Biogen Idec, Inc. (Massachusetts) Demonstrates Commitment To Advancing Hemophilia Research And Care At Annual American Society of Hematology Meeting
December 3, 2013
 · 
1 min read
Policy
FDA Extends Review Of Biogen Idec, Inc. (Massachusetts)'s Hemophilia Drug ALPROLIX™
December 2, 2013
 · 
2 min read
Genetown
Biogen Idec, Inc. (Massachusetts) To Present At The 2013 Deutsche Bank BioFEST
November 26, 2013
 · 
1 min read
Policy
Biogen Idec, Inc. (Massachusetts) Release: CHMP Determines Dimethyl Fumarate In TECFIDERA® To Be A New Active Substance In The European Union
November 22, 2013
 · 
1 min read
Drug Development
Biogen Idec, Inc. (Massachusetts) and Swedish Orphan Biovitrum Release: Leading Hematology Journal Publishes Pivotal Eloctate Tm Data That Demonstrated Efficacy And Safety Of Investigational Long-Lasting Therapy For Hemophilia A
November 13, 2013
 · 
8 min read
Policy
Biogen Idec, Inc. (Massachusetts), Swedish Orphan Biovitrum Hemophilia Drug Delayed As FDA Seeks More Info
November 12, 2013
 · 
3 min read
Business
Galapagos NV Subsidiary BioFocus DPI Lines Up $31 Million Windfall From Agreement With Biogen Idec, Inc. (Massachusetts)
November 12, 2013
 · 
4 min read
Genetown
Biogen Idec, Inc. (Massachusetts) to Present at the Credit Suisse Healthcare Conference
November 6, 2013
 · 
1 min read
Business
Biogen Idec, Inc. (Massachusetts)Total Revenues Increased 32% to $1.8 Billion in Third Quarter; Company Raises 2013 Financial Guidance
October 28, 2013
 · 
1 min read
Business
Isis Pharmaceuticals, Inc. Earns $10 Million Milestone Payment From Biogen Idec, Inc. (Massachusetts) for Advancement of ISIS-DMPK Rx to Treat Myotonic Dystrophy
October 16, 2013
 · 
5 min read
Load More